Investigational drug · Phase 2
RABI-767
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Pancreatitis.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "RABI-767"
First trial start
2024
Jun 28, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RABI-767", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Pancreatitis
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RABI-767" as an intervention, largest first.
Panafina, Inc.Industry
NCT06080789 · 36 participants (planned) · Start Jun 28, 2024 · Primary completion Dec 2026
Drug: RABI-767 · For: Acute Pancreatitis
Sites: Little Rock, Arkansas; Los Angeles, California; Aurora, Colorado · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Acute Pancreatitis
- SGC001Phase 22 trials
Beijing Sungen Biomedical Technology Co., Ltd · Acute Anterior ST-Segment Elevation Myocardial Infarction, Acute Pancreatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.